Please login to the form below

reimbursement models

This page shows the latest reimbursement models news and features for those working in and with pharma, biotech and healthcare.

UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme

The antibiotic treats infections caused by aerobic Gram-negative bacteria. Shionogi’s novel antibiotic Fetcroja has been selected for inclusion in a pilot subscription reimbursement scheme, launched by the UK’s ... Shionogi strongly supports the

Latest news

Bluebird bio launches beta thalassaemia gene therapy Zynteglo in Germany

With the rapid development of novel gene therapies also comes the need for new payment models that can accommodate the high cost of accessing these treatments. ... A report from The Alliance for Regenerative Medicine (ARM) published in July last year
The business case for patient engagement

b) Reimbursement models are evolving. Until recently, reimbursement was rather indirect, for example, by using digital medicines for safeguarding pay-for-performance deals and value-based reimbursement models. ... The next step is direct reimbursement of
UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D

Our NHS is in a unique position to take a global lead in testing new payment models. ... The pilot scheme also reflects a new willingness and capability in the UK to try out new reimbursement models, primarily led by NHS England.
Europe urged to adapt faster to gene therapy challenges

Existing models include conditional reimbursement, such as England’s Cancer Drugs Fund and Scotland’s fund for ultra-orphan drugs. ... The report recommends a number of key measures, including:. A quick adoption of new payment models such as
Europe responding to gene therapy challenge, but picture remains fragmented

The Advanced Therapies &Regenerative Medicine congress, hosted by Terrapinn on Thursday, brought together a panel of experts who discussed emerging reimbursement and financing models in the US and Europe. ... However the changing dynamics of the pipeline

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest Intelligence

Man vs microbe: the fight against antimicrobial resistance

The payer perception. On average, payers rate innovative reimbursement models as being slightly more impactful than amending HTA pathways at addressing AMR (Figure 1). ... Payers recognise value in the approaches adopted by the UK and Germany, suggesting
Reimbursement ≠ patient access

In our experience, creating future- proof reimbursement strategies now relies heavily on achieving two critical components. ... Launch activities will have to include data capture on a product’s performance and patient outcomes to satisfy future
Building a brighter future with patient support programmes

This opens up the opportunity to run a really targeted clinical study and get strong outcomes, which lifts a drug’s chances of succeeding through the regulatory process and reimbursement.”. ... Reports by analysts Deloitte underscore the value of
Assessing the risks in annuity pricing models

Any of these issues can increase cost or risk. Adapting pricing and reimbursement models to accommodate these therapies could be a significant challenge, especially for higher-cost drugs or those involving ... Manufacturers will need to restructure
No incentive for a cure

Each of the different models are variations of a fee-for-service reimbursement model, which have evolved to meet the needs of chronic illnesses. ... Incremental changes may work in the short-term. Incremental changes include solutions such as

More from intelligence
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest from PMHub

Reflections of a Fireside Chat from the World Orphan Drug Congress 2020

As a business, Orchard Therapeutics want to introduce as many therapies as possible and, in order to enable a broader reach, are eager to work with regulators to explore reimbursement models
Innovation in pharma: the highs and lows of the current healthcare economy

The cycle of behavioural change. It’s already certain that more pragmatic reimbursement models will be required to deal with the cost of these new treatments as upfront payment will be